Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04088773 · ClinicalTrials.gov registry record
Biomarkers of Intestinal Fibrosis in Small Bowel Crohn's Disease
A clinical trial of Crohn Disease, sponsored by Children's Hospital Medical Center, Cincinnati.
- Active
- Registry status
- 232
- Enrollment target
- 4
- Study locations
NCT04088773: Active study of Crohn Disease, sponsored by Children's Hospital Medical Center, Cincinnati.
NCT04088773 is a study of Crohn Disease that is active but no longer recruiting, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 232 participants, above the 202-participant average among 71 other Crohn Disease trials with a reported enrollment target (15% higher). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04088773, a study of Crohn Disease, is active but no longer recruiting, sponsored by Children's Hospital Medical Center, Cincinnati.
- ACTIVE NOT RECRUITING
- Registry status
- 232 participants
- Enrollment target
- 4
- Study locations
Study Summary
This research study will evaluate if specific blood, stool and MRI tests can tell the difference between bowel wall inflammation without scarring and bowel wall inflammation with scarring that can cause bowel blockages requiring surgery.
Primary Outcome
compare MTR values between Aim 1 and Aim 2 cohorts
Conditions Studied
Interventions
- DIAGNOSTIC_TEST blood biomarkers
- DIAGNOSTIC_TEST stool biomarkers
- DIAGNOSTIC_TEST MRI imaging
Study Locations (4)
Georgia
- Emory/Children's Healthcare of Atlanta - Atlanta
Michigan
- Michigan Medicine - Ann Arbor
Minnesota
- Mayo Clinic - Rochester
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2019-11-01 |
| Est. Completion | 2026-06 |
What the registry record for NCT04088773 still lists
NCT04088773 is an observational study that tracks outcomes without assigning an intervention. The registered 232 participants enrollment target is mid-sized for trials with a published cap, above the 202-participant average among 71 other Crohn Disease trials with a reported enrollment target (15% higher).
The record links to 1 condition, with Crohn Disease appearing as the primary indexed condition, and to 3 interventions - of which blood biomarkers is the first listed.
NCT04088773 reports a single indexed study location in Georgia, Michigan, Minnesota.
Frequently Asked Questions
What is clinical trial NCT04088773 about?
NCT04088773 is a clinical study titled "Biomarkers of Intestinal Fibrosis in Small Bowel Crohn's Disease". This research study will evaluate if specific blood, stool and MRI tests can tell the difference between bowel wall inflammation without scarring and bowel wall inflammation with scarring that can cause bowel blockages requiring surgery.
What is the current status of trial NCT04088773?
This trial is currently active not recruiting. The enrollment target is 232 participants. The study started on 2019-11-01. Estimated completion is 2026-06.
What conditions does trial NCT04088773 study?
This clinical trial studies the following conditions: Crohn Disease.
What interventions are being tested in trial NCT04088773?
The interventions under investigation include: blood biomarkers (DIAGNOSTIC_TEST), stool biomarkers (DIAGNOSTIC_TEST), MRI imaging (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04088773?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04088773 being conducted?
This trial has 4 study locations across Georgia, Michigan, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04088773's enrollment target sits among peer trials
232 17th of 71 higher than 55 of 71 other Crohn Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Crohn Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
RECRUITING · NA
-
Low Dose IL-2 for the Treatment of Crohn's Disease
RECRUITING · Phase 1
-
Registry and Biorepository for IBD in Central Texas
RECRUITING
-
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01356290 · 232 participants · Phase 2
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
- NCT04753359 · 232 participants · NA
Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
- NCT04770870 · 232 participants · NA
Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System
- NCT05948943 · 232 participants · Phase 2
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI